On April, 22th, the BeCAT and Si-M were inaugurated in Berlin—two important beacons for our region. What they share is the goal of developing effective personalized therapies for diseases that have so far been considered incurable.
16.-20.11.2026
New study presents theoretical framework to address a conceptual gap in our understanding of ADHD
According to a TU Berlin study, ChatGPT models tend to make overly cautious recommendations, and are currently inadequate for the targeted management of patients in healthcare systems
On the occasion of German Biotech Days (DBT) 2026 in Leipzig, the Working Group of the German BioRegions once again presented its renowned Innovation Award on 21 April 2026. For the past 19 years, the award has honored innovative biotechnological…
At the heart of Brain City Berlin, a new Future Site is taking shape: the Health Innovation Quarter Berlin-Mitte. Here, science, industry and startups are working together on the health innovations of the future. The initiative was founded by Charité…
U.S. biopharmaceutical company Gilead has entered into a definitive agreement to acquire Tubulis GmbH. Tubulis was spun off in 2019 from the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) and LMU Munich and develops next-generation…
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers have succeeded in developing a so-called nanobody that penetrates directly into human cells and can repair the chloride channel…
APPLICATION/NOMINATION PERIOD: 02 FEBRUARY - 30 APRIL 2026 (EXTENDED❗️)
Researchers from the German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE) and other partner institutions of the German Center for Diabetes Research (DZD) have now identified a previously unknown function of the PICALM protein in skeletal…
